Table 3.
Association between meEGFR expression and clinical-pathological and molecular factors (N = 164, exclude 12 cases that had no data on meEGFR expression)
| Variable | meEGFR | P value | |
|---|---|---|---|
|
| |||
| Low/No expression | High expression | ||
| Age (n = 164) | |||
| < 50 years | 25 (28.4%) | 21 (27.6%) | 0.91 |
| ≥ 50 years | 63 (71.6%) | 55 (72.4%) | |
| Sex (n = 164) | |||
| Female | 36 (40.9%) | 36 (47.4%) | 0.41 |
| Male | 52 (59.1%) | 40 (52.6%) | |
| Site (n = 164) | |||
| Right-sided | 34 (38.6%) | 27 (35.5%) | 0.68 |
| Left-sided | 54 (61.4%) | 49 (64.5%) | |
| Differentiated (n = 161) | |||
| Moderate | 45 (56.3%) | 52 (64.2%) | 0.30 |
| Poorly | 35 (43.8%) | 29 (35.8%) | |
| KRAS (n = 163) | |||
| wt | 73 (83%) | 51 (68%) | 0.03 |
| mt | 15 (17%) | 24 (32%) | |
| NRAS (n = 136) | |||
| wt | 76 (100%) | 56 (93.3%) | 0.02 |
| mt | 0 (0%) | 4 (6.7%) | |
| BRAF (n = 150) | |||
| wt | 68 (84%) | 58 (84.1%) | 0.97 |
| mt | 13 (16%) | 11 (15.9%) | |
| PIK3CA (n = 142) | |||
| wt | 73 (90.1%) | 51 (83.6%) | 0.25 |
| mt | 8 (9.9%) | 10 (16.4%) | |
| MSI (n = 99) | |||
| MSS/MSI-L | 41 (91.1%) | 51 (94.4%) | 0.52 |
| MSI-H | 4 (8.9%) | 3 (5.6%) | |
wt: wild type, mt: mutation.